We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Collagen Deposition-Promoting Gene Linked to Cancer Metastasis

By LabMedica International staff writers
Posted on 07 Mar 2017
Cancer researchers have identified a gene that when active promotes the metastasis of breast cancer (BC) by increasing collagen deposition by breast cancer-associated mesenchymal stem/multipotent stromal cells.

The molecular mechanism underlying the increased collagen disposition was not known. More...
To correct this deficiency, investigators at the University of Michigan analyzed the activity of the collagen receptor discoidin domain receptor 2 (DDR2) gene, which is essential for stromal-BC communication. They looked at levels of ddr2 enzyme activity in cells at sites of BC metastasis as well as working with the slie line of mice, which had been genetically engineered to lack the DDR2 gene.

The investigators reported in the January 31, 2017, issue of the journal Cell Reports that in human BC metastasis, DDR2 was consistently upregulated in metastatic cancer cells and in multipotent mesenchymal stromal cells (MSCs). In MSCs isolated from human BC metastasis, DDR2 maintained a fibroblastic phenotype with collagen deposition and induced pathological activation of DDR2 signaling in BC cells.

Loss of DDR2 in MSCs impaired their ability to promote DDR2 phosphorylation in BC cells, as well as BC cell alignment, migration, and metastasis. Female ddr2-deficient mice homozygous for the slie mutation showed inefficient spontaneous BC metastasis.

“We discovered that DDR2 mediates the communication between mesenchymal stem cells and cancer cells,” said senior author Dr. Celina Kleer, professor of pathology at the University of Michigan. “When we inhibit this receptor in the mesenchymal stem cells, it tricks the cancer cells. The cells do not align, they do not migrate, and they do not metastasize efficiently. This suggests a possible therapeutic target. Our goal is to identify a way to interrupt breast cancer metastasis growth and invasiveness, either to prevent metastases from forming or to keep them at bay when they do develop. The microenvironment is a rich opportunity to better understand why cancer metastasizes and begin to attack that process.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
All-in-One Molecular System
AIO M160
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.